Patritumab Deruxtecan — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

9 Recruiting

5 Completed trials

5 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 7 Phase I/II: 5

Oversight events:

4 serious breaches 2 unexpected events across 3 trials

View oversight register →

Indications tested

Hormone receptor positive HER2 negative breast cancer 2 Triple negative breast cancer 1 EGFR gene mutation 1 Rhabdomyosarcoma 1 Hormone receptor positive breast cancer 1 Hepatoblastoma 1 Lung neoplasm malignant 1 Gastrooesophageal cancer 1 Human epidermal growth factor receptor negative 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 8 Daiichi Sankyo Inc. 3 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Medica Scientia Innovation Research S.L. 1 Solti Group 1

All trials

14 total

A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting

2024-512248-47-00 Phase I/II 6 countries Merck Sharp & Dohme LLC
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting

2025-520582-51-00 Phase III 7 countries Merck Sharp & Dohme LLC
A clinical study of patritumab deruxtecan in people with breast cancer Recruiting

2024-514376-40-00 Phase II 1 country Merck Sharp & Dohme LLC
A clinical study of patritumab deruxtecan (HER3-DXd) in children with cancer (MK-9999-01C) Recruiting

2024-518771-66-00 Phase I/II 12 countries Merck Sharp & Dohme LLC
Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT Recruiting

2023-508233-14-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Clinical trial of patritumab deruxtecan in people with gastrointestinal cancers Recruiting

2024-512442-41-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting

2023-509306-29-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
Substudy 06C: Combination Therapies in Gastroesophageal Adenocarcinoma Recruiting

2023-509307-33-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting

2023-507641-29-00 Phase II 8 countries Daiichi Sankyo Inc.
A clinical study of pembrolizumab and other treatments for non-small cell lung cancer (MK-3475-01G) Ended

2024-515772-12-00 Phase II 5 countries Merck Sharp & Dohme LLC
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended

2023-503403-28-00 Phase II 1 country Solti Group
Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF… Ended

2023-507964-38-00 Phase III 10 countries Daiichi Sankyo Inc.
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended

2024-512238-13-00 Phase II 6 countries Daiichi Sankyo Inc.
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Phase II 2 countries Medica Scientia Innovation Research S.L.

Showing 1–14 of 14 trials

← All drugs A–Z